Voluntary pre-transparency - Expansion with purchase of PAT and LET modules, continuation of software maintenance of the RayStation irradiation planning system (TPS) and including options on modules Text automatically translated in your browsing language Automatically translated

Description This concerns the publication in case of voluntary ex ante transparency of the intention to award the contract for extension with the purchase of three (3) PAT and two (2) LET modules, continuation of software maintenance for 10 years of the RayStation irradiation planning system (TPS) and including options on modules. The extension with purchase including maintenance and options can be awarded directly on the basis of an exception to the tendering obligation because the UMCG can rely on Article 2.32 paragraph 1 sub. AW. This article describes that when competition is not possible for technical reasons, an exception to the obligation to tender arises. Motivation UMCG provides the best possible proton therapy from its point of view and is also obliged to do so in the context of the Model-Based comparison with the best possible photon therapy. In order to remain state-of-the-art, two new techniques are needed for which modules must be purchased in the TPS: PAT (Proton Arc Therapy) and LET (Linear Energy Transfer) based optimization. The required modules only function as part of a TPS integrated into the departmental processes, in our case RayStation. In addition, the module for LET-based optimization is uniquely only available in RayStation. Market exploration taught us that the necessary functionality for PAT can also be offered by another company as part of its TPS. However, the LET and the PAT modules should be used in one TPS and thus jointly procured, as otherwise major or insurmountable interoperability problems would be introduced when a part of the proton irradiation plans would inevitably have to be processed in one TPS and another part in another TPS, or when one and the same irradiation plan would have to be processed alternatingly in both TPS. More than one TPS would thus completely block the optimal quality required for the treatment and which is also the starting point of the Model-Based comparison. Purchasing via a tender from another TPS in addition to RayStation to allow the necessary modules (with the exception of LET-based optimization for which RayStation will continue to invite you anyway) to function in it is impracticable in terms of development time of technology and in terms of lead time of patient treatment. Switching to another TPS would cost a similar multi-year development time investment as the introduction of proton therapy in the UMCG, in which UMCG-RT would be as much behind the best possible proton therapy. Illustrative in this regard is that the other proton therapy institutes in the Netherlands also use RayStation as their TPS. In doing so, the inevitably complex and limited interoperability between two TPS systems would cost so much more time for treatment preparation that an essential quality criterion of (proton) radiotherapy would be unacceptably compromised. Given the need to continue with RayStation as a TPS (unique LET optimization, ensure engineering development, limit treatment preparation lead time), an extension of the software maintenance by 10 years from 2025 is necessary. Upgrades of the RayStation TPS with modules that can reasonably be expected in the coming years as options included in the intended award as these modules do not apply outside the RayStation TPS. The choice to expand with the purchase of PAT and LET modules, the continuation of software maintenance of the RayStation TPS and including options on modules is therefore the only possibility at the time of this publication for the developments necessary for the UMCG in the irradiation planning of its irradiation techniques. Procedure This notice is used only to make the intended choice of procedure known in advance to the market in order to give interested parties the opportunity to raise any objections. If, despite the above reasons, interested parties wish to object to the above-mentioned intention, they must submit a reasoned objection to the continuation of this proceeding within 20 calendar days of the publication of this notice. For this you can use the e-mail address as stated in the contact details. The UMCG will take any objection into account in its assessment. If no objection has been raised during this period, the rights of undertakings to challenge the proposed procedure will lapse. Text automatically translated in your browsing language Automatically translated

48180000 - Medical software package

33000000 - Medical equipments, pharmaceuticals and personal care products CVP code deduced from the text of the procedure AI-generated